Posted: May 13, 2013 10:43 AM by AP
WASHINGTON (AP) - A subsidiary of an Indian pharmaceutical company has agreed to pay $500 million fines and civil penalties for selling adulterated drugs and lying about tests to federal regulators, the Justice Department said Monday.
The guilty plea by Ranbaxy USA Inc. represents the largest financial penalty by a generic drug company for violations of the Federal Food, Drug and Cosmetic Act, which prohibits the sale of impure drugs, prosecutors said.
Ranbaxy, a subsidiary of Ranbaxy Laboratories Limited, admitted that it made and sold impure drugs at two manufacturing sites in India. The batches of adulterated drugs included generic versions of an antibiotic and other medications used to treat severe acne, epilepsy and nerve pain.
The company agreed to a fine and forfeiture of $150 million as well as an additional $350 million penalty to settle civil claims that it submitted false statements to Medicaid, Medicare and other government health care programs.
The company also admitted making false statements to the Food and Drug Administration about dates of stability testing, which detect impurities of a drug and to determinate appropriate storage conditions of it.
Click here to submit a news tip to us!
Become a Facebook Fan!
Help those in need this holiday season
Win! Win! Win!
Wise Local Marketing!
Get news, weather and more on your smartphone and tablet!
Get texts for news, traffic, deals and more!
Sign up on KVOA.com for newsletters, exclusive deals, and more!
What's happening on News 4 @ 4
Stories and videos with Kristi's Kids
Check out the latest events FC Tucson has scheduled.
Let us help grow your business
Digital Channel 4.2
What's on KVOA and when!
Contact info for our department heads
KVOA's on air personalities!
Work at News 4 Tucson
Complete feeds of all KVOA.com stories
FCC Public File of Records, Reports, and More